The Second Annual IBC International Conference on

December 16-18, 1991 Omni San Diego Hotel San Diego, CA

Organized by: International Busines..4' Communications

me USA Conference Inc. 8 Plea ant Street, Bldg. D South Natick, Mass. 01760 (508) 650--4700

1 of 6 Celltrion, Inc., Exhibit 1120

WELCOME

IBC USA Conferences welcomes you co Antibody Engineering.

No meeting is truly successful if it simply serves the purpose of transferring information. We hope in[eractions between lhe speakers and Lhe audience will be1p you gain insights rhac you can use today.

We strongly encourage your participation throughout the conference and have allowed time for you ~se questions co the speakers. Ample rime for informal interactions has also been allocaced oughouc the day. These encounters will complement both the speaker pn:sentations and the written erial.

Our staff members are available throughout the conference to provide assiscance. Please do not ~tate [Q call on us. We thank you for joining us!

~J!Jl Phillips Kuhl Conference Director

6# ~~-/ 44-/ Gail Scho Conference Manager

Christine Andrews Susan Hamano Conference Coordinacor Conference Coordinator

!BC USA Conferences

~ Delegates are required to wear their bat$ges at all times. Those without their badges will not be admitted.

2 of 6 Celltrion, Inc., Exhibit 1120

ANTIBODY ENGINEERING

Schedule of Events

Welcome & Introduction Speaker Contacts Speaker Presentations

Sunday, December 15, 1991

p.m.-10:30 p.m. Early Registration

Monday, December 16, 1991

~. a.m.-8:30 a.m. Rtgmrauon, Poster St1-up & Cof!u

ENGINEERING TO AVOID HAMA 8:30 CHAIRMAN'S OPENING REMARK

Dr. Sherif L Morrl\on, Pro/tsS()r of M1crobwlor1 and Molecular Gene1irs, Member of the Moucwlar Bialogy /1U1il11'U, UCLA

8:35 HUMANIZED Al\TIBODIES FOR THERAPY Dr. Cary Qurrn, Vice Preside.111, Resca~h. Proteut Design Lab.f, Inc

9:05 FRAMEWORK CHOICE & RESIDUE SUBSTlTUTION FOR HUMANIZED VENEERED ANTIBODIE Dr. G~orae E. Mark ID, D;,1ec1or, Ct'llular &. Mole4ular Bwlofl), Mud SJi/Jrp &. DoivnL RCRarch LaborOJOriu

9:35 USE OP A VACCINIAfli SYSTEM TO RAPIDLY ANALYZE HUMA1'1ZED & OTHER ENGINEERED SJNGLE-CHArN FV'S Dr. S)d Johnson, R1.1~h Sc~NISI. Mcdlmnu

2:50 IN VITRO AFFINITY MATURATION BY SITE DIRECTED MUTAGENESIS Dr. WUJlam D. Hme, CN.ef Sc10tJiflc Officer. IXSYS. Inc

3:20 Rtfru hmen1 Break & Postt rs

4:00 ANTIBODY ENGINEERING FOR MICROBIAL EXPRESSION & THERAPEUTIC USE Dr. A mold H. Hon.tu, Dvt!ctor of Molttwlar Mu:robiology, XOMA Corpora11.0n

4:30 RECENT ADVANCES WITH CATALYTIC A.NTIBODIES Dr. Mark A.. Gallop, S1ajf Scienlist, B ioorganic CJmmstry, A]hm.tlx Rtsearch /ns1ui.u

5:00 ORAL PRESENTATION OF SELECTED POSTERS

5:15 PANEL DISCUSSION

5:45 Clo.st! of Day Ont

Tuesday, December 17, 1991

7:30 Coffu &: Pos11m.

Bl-SPECIFIC & Bl-FUNCTIONAL

8:00 CHAIRMAN' S RF.MARKS Dr. SMrle L. Murraon, Professm of M1uob1olo1fY ll1lil Molt!t:ulcv Gmt1ics. Mtmbtr of'"' Mokcular Biology /11S1itwie. UCLA

8:05 OVERCOMING ANTIDODY BLOCKAGE USING Bl-SPECIFIC ANTIBODIES Dr. Satban 8 . Dlnces, \'ice Prtsidefll Mtd.aru. Inc

8'.35 RF.SF.ARCH & CLJNICAL EXPERIEJ\CE WITH 81-SPEc m c ANTIBODIES Dr. Joesph G. Major, Sef'l.IOr Resrwch Sc11n11s:, H}bmcch, /ncorporaud

9:05 TARGETING C YTOTOXJCIT\' WITH A Bl-SPECIFIC ANTIBODY DIRECTED TO C-ERB-2 & HUMAN FC"y RECEPTOR Ill Dr. Dnld 8 . Ring, SMWr Sc1cnJut. Dvecior. Dt:JX1rlme1t1 of lmnumoloi). Ct!1w.t CorportJJ1on

9 35 Refrtshmem BreaJ. & Pos1ers

10:15 PRODUCTION OF A SINGLE-CHAIN BlSPECIF1C ANTIBODY Dr. Andttw J. T. Gfl>rgr , xpu~n1al lmnuuiolou Branrh, /\aJwnal CanU /n.rriwu , Na1iona/ lnstilwu.s of H t:ahh

10:45 GENETIC ENGINEERING Of ASTIBODIES FOR NOVEL FUNCTIONS Dr. her le L. ~orris.on

11 :15 ORAL PRESENTATION Of SELECTED POSTERS

l 1:30 PANEL DL'iCL'SSION

12:00 lunch Br~alr.

HUMAN MONOCLONALS

1:15 C HAIRMA1' ' S RF.MARKS Dr. \1urk C. Ght.~} . Edi1or 111 -Clut:/, Humlll1Afllibodi~s aNJ llybridomaJ and Prt:sidm. Sc1-CloM, Jnc.

1:20 HUMA"li MONOCLONAL IMAGJ'iEERJl\G Dr. !\tan. C. Gia&)

1:50 HUMA1' A'ITJBODIES B\' RF:PERTOIRE L'LO!' l :"JG Dr. Carl05 F. B .. rb~, .>\.uu1an1 Prvfe.rn., Scripr" Re\tJn h Jnswu.u

4 of 6 Celltrion, Inc., Exhibit 1120

2:20 PRODUCTION &c APPLICATION OF HUMAN MONOCLONAL ANTIBODIES Dr. S. M. Jwasa, Ru~ardt MDNJ10. Bwlog)' Res~n l.AboratonCJ, TaiwJJJ ClwluC41 /ndlUlria, LJd.

2:50 Refreshment Break & Postus

3:30 IN VITRO IMMUNIZATION METHODS FOR PRODUCTION OF HUMAN IGG MONOCLONAL ANTIBODIES Dr. Paula Boerner, Dirttl"' of Celi Baolog:-. IXSYS. Inc

4:00 DEVELOPMENT OF A HUMAN lrt1MllNOGLOBULIN TRANSGENIC MOUSE Dr. Slls Loabrr&, SotJDT Scu:fllUt. Genl'lw.rm buul'IQliQNJJ

4:30 ORAL PRESENTATION OF SELECTED POSTERS

4:45 PANEL DISCUSSION

5: 15 POSTERS

6:00 Cocklail Rtception

7:30 Close of Day T"'"'

'tVednesday, Decernber1B. 1991

7:30 Coffu & Posrtrs

CLINICAL EXPERIENCE

8:00 CHAIRMAN'S REMARKS Dr. Albfrt F. LoBugflo, D1ncror Compr~MllJm Cancer Cefllu, Professor of MemciM, Univvsll) of Alabama a18inn111gltam

8:05 PHARMACOKINETICS & 11.fMUNE RESPO~SE OF MURINE & CHIMERIC ANTIBODIES Dr. AJbtrt F. LoBugJlo

8:35 CLINICAL EXPERIENCE WITH THE L6 A"fflCARCINO\!A ANTIBODY Dr. Dalt' E. Yt!lton, SciLNISI, Brmol-M)u.r Sq1,.bb Pharm.xewicat Research l1U11lllll

9:05 CLINICAL RESULTS WITH CHIMERIC & HUMAN MONOCLONAL ANTIBODIES Dr. Jamti N. Wood~, Suu01T \-'iu PresuitnJ, C miocor. ll'IC

9:35 Refreshment Bnak and Poscers

10:15 PATIE1'T RESPONSE TO CHIMERIC 872.3 l>r. Ttrt) S. Bakrr, Pr111C1pat Sc~111is1. Crlltuh, ud

10:45 IJliTERNAL IMAGE ANTIGEJ'liS AS THERAPEUTIC MODA.LITTF.S FOR CANCER & INFECTIOUS DISEASES Dr. Samurl D. Waksal, P~s1dU1J and CEO. JmCJ.oM 51.rtmu Inc

11:J5 ORAL PRESENTATION OF ELECTED POSTER

11 :30 PA!liEL DI Cl: 'SIOJ'li

12:00 Clos~ of Conftr~nu

5 of 6 Celltrion, Inc., Exhibit 1120

CHOOSING THE BEST FRAMEWORK TO USE IN THE 'HUMANIZATION' OF AN ANTIBODY BY CCR-GRAFTING: SUGGESTIONS FROM 3-0 STRUCTURAL DATA

Eduardo A. Padlan Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, U.S.A.

SUMMARY

In order to ensure the preservation of antigen-binding properties. when an antibody is 'humanized' by CDR-grafting, all the framework residues, that could influence the structure of its combin ing site, must be reta ined. Examination of the structures of various Fabs reveals that those residues are different for different antibodies, emphas1Z1ng the need for a we ll-characterized, three-d1mens1onal structure to serve as a gu ide during 'humanization'. A hypothetical 'humanization' by CDR-grafting of the mudne antibody, J539, that attempts to preserve the ligand-binding prupe:1ties of th e molecule: , aer.1onstrates that hurnan 1mmunoglobulrn sequences are available that. w1 h on ly a few mu ations, could serve as the best framework for the 'humanization' of this antibody.

6 of 6 Celltrion, Inc., Exhibit 1120